Summary Results using the same drug in phase II studies of treatment in ovarian cancer vary widely. An analysis of five phase II studies with a total of 93 patients was carried out to determine whether factors other than the efficacy of the drug affect response. The drugs for the phase II studies were chosen on the basis of in vitro activity or previous activity in humans. Univariate analysis showed that several factors were of significance in predicting response. The most significant was interval from the end of previous treatment to entry into a phase II study. Others were the original presenting stage of the patient, the second line treatment given and the best previous response to therapy. In multivariate analysis, however, only two factors were shown to be of importance which were interval and the FIGO stage of the patient. Using these two variables the discriminant analysis predicted 89% of those who did not respond and 75% of those who did, with an overall correct prediction of 85%. The importance of interval is emphasised by the observation that the response rate for those patients who progressed on treatment or who relapsed within 3-6 months of primary therapy had a response rate of <10%. Future phase II studies should probably exclude patients in this category, since the chance of their responding is very low.
The outlook for patients suffering from advanced ovarian cancer is poor, with fewer than 20% of patients with stage 3 or stage4 disease surviving more than 5 years (Katz et al., 1981) . The disease is sensitive to chemotherapy but in advanced disease the role of chemotherapy is palliation in the majority of patients (Neijt et al., 1986) .
Since the majority of patients will respond to established chemotherapy agents, it is difficult ethically to evaluate new agents as first line treatment. Evaluation of new agents is confined to patients relapsing or progressing at the end of primary therapy. Studies of a wide range of chemotherapeutic agents have shown widely varying results (Ozols & Young, 1984) . In studies of cisplatinum, for example, response rates in the range of 15-50% have been observed (Thigpen & Blessing, 1985) and in evaluations of the anthracenedione mitoxantrone response rates from 0 to 28% have been seen (Lawton et al., 1978a; Muss et al., 1984; Hilgers et al., 1984) .
Such variations in response rates suggest that factors other than the activity of the drug may be involved in determining whether a patient is likely to show response to a new drug. This has implications for the evaluation of new drugs, and may explain why some studies have failed to detect active drugs.
In an attempt to identify whether such factors exist we have examined retrospectively a group of patients from this centre treated in a number of phase II studies over a period of 4 years. We have aimed to identify factors which predict patients who will respond to chemotherapy.
Patients and methods
A total of 92 patients were entered into five phase II chemotherapy trials from 1983 to 1987 (Lawton et al., 1985 (Lawton et al., , 1986 (Lawton et al., , 1987a Redman et al., 1988) . These studies had common entry criteria; patients had biopsy proven epithelial ovarian carcinoma, had received at least first line treatment and had either progressed on or relapsed after therapy. Patients, though symptomatic, were medically fit to receive treatment and has an anticipated life span in excess of 2 months. Patients had WHO performance status of 0 or 1.
Response was assessed using standard UICC criteria. The treatments being evaluated were selected on the basis of in vitro cytotoxicity data, and previous single agent phase II data. The number of patients in each of the phaseII trials and the characteristics of the responding and non-responding patients are shown in Table I .
The significance of differences between the responders and non-responders in age and in the interval from the cessation of previous treatment to the phaseII treatment was tested using the Mann-Whitney U test. Differences in the discontinuous variables were tested by calculating x2 from the two way contingency tables.
The variables used in a discriminant function analysis to determine the best combination of characteristics for classifying patients into responders and non-responders are shown in Table II . A number of transformtions of age and interval were assessed. The computer package of Biomedical Programs (BMDP) was used for these analyses.
Patient classifications based on the best discriminant function were compared with observed response to phase II treatment.
Results
The univariate analysis suggested that patients who responded in phase II studies had a longer interval from completing prior therapy to entering the phase II study, had less advanced disease at initial presentation, and had disease that had previously responded to prior treatment. The type of phase II regimen also influenced the number of responses seen, with the combinations including cis-platinum having a higher response rate.
In the discriminant analysis, the interval from the end of prior treatment to entering a phase II study was clearly the variable giving the greatest discrimination between responders and non-responders, with F ratios more than double those of the other variables. The transformations of interval all gave better discrimination than the raw scale. The biggest difference between the groups was shown by the square root of interval and this variable was entered into the discriminant function.
Having entered interval into the function, previous response and type of second line treatment, which were correlated with interval, were no longer significant. However, FIGO stage remained highly significant and was able to Br. J. Cancer (1989), 59, 650-653 ,'. The Macmillan Press Ltd., 1989 S= score for patient classification into responder group --7.9 + 8.9 x stage value + 1.7 x interval value and 2 score for patient classification into non-responder group = -6.9 + 11.6 x stage value + 0.6 x interval value where the stage value for patients with FIGO stage I or II at presentation is 0 and with FIGO stage III or IV is 1; and the interval is the square root of the interval from the end of prior therapy to entering the phase II study in months.
Each of the patients was classified into the group for which they had the highest score (Table III) . The function correctly classified 77.4% of patients who responded to chemotherapy and 88.5% of those who did not, with 84.8% being correctly classified overall.
Interval was by far the most important variable, and although FIGO stage gave a statistically significant improvement in discrimination between responders and nonresponders, it may not usefully improve the percentage These observations relate primarily to the evaluation of phase II treatments. The decision whether to treat a particular patient who has relapsed after primary therapy for ovarian cancer must remain with the clinician. The observations of this study, however, give some indication of the probability of response and may also influence the kind of treatment given.
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